Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer
IHC3 is able to define prognostic groups in patients with node-negative, HRpos/HER2neg eBC. Node-negative patients with a high IHC3 score had the worst prognosis, which was comparable to that of node-positive patients described in recent trials. This simple and cost-effective tool could thus potentially aid in identifying patient groups for innovative therapeutic approaches.
Authors
- Daniel Anetsberger
- Matthias Ruebner (ORCID: https://orcid.org/0000-0002-2408-1138)
- Hanna Huebner (ORCID: https://orcid.org/0000-0001-6889-1493)
- Peter A. Fasching (ORCID: https://orcid.org/0000-0003-4885-8471)
- Felix Heindl (ORCID: https://orcid.org/0009-0000-6478-3313)
- L Häberle
- Sabrina Uhrig
- K Seitz
- Julius Emons (ORCID: https://orcid.org/0000-0002-2520-4443)
- Ramona Erber (ORCID: https://orcid.org/0000-0003-0315-1229)
- Chloë Goossens (ORCID: https://orcid.org/0000-0002-0999-8562)
- A. Hartmann
- CC Hack
- MW Beckmann
Institutions
- Universitätsklinikum Erlangen (DE)
- Comprehensive Cancer Center Erlangen (DE)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103963
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.29